A detailed history of Capula Management LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Capula Management LTD holds 17,276 shares of BMY stock, worth $981,276. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,276
Holding current value
$981,276
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $685,166 - $894,033
17,276 New
17,276 $894,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $53,643 - $59,563
-842 Reduced 1.18%
70,603 $4.52 Million
Q1 2023

May 10, 2023

SELL
$65.71 - $74.53 $10.1 Million - $11.5 Million
-153,868 Reduced 68.29%
71,445 $4.95 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $15.4 Million - $18.3 Million
225,313 New
225,313 $16.2 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $74,290 - $81,819
1,023 New
1,023 $79,000
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $1.8 Million - $2.1 Million
-33,586 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $965,772 - $1.13 Million
16,322 Added 94.54%
33,586 $1.99 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $857,205 - $933,497
13,846 Added 405.09%
17,264 $1.15 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $402,621 - $452,830
-6,785 Reduced 66.5%
3,418 $216,000
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $4.93 Million - $5.58 Million
-85,355 Reduced 89.32%
10,203 $633,000
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $1.4 Million - $1.64 Million
-25,566 Reduced 21.11%
95,558 $5.62 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $5.62 Million - $8.17 Million
121,124 New
121,124 $6.75 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Capula Management LTD Portfolio

Follow Capula Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Capula Management LTD with notifications on news.